Dalbavancin Side Effects: What Studies Report

What dalbavancin is in the published literature

Dalbavancin is a semi-synthetic lipoglycopeptide antibiotic with activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus. Much of the discussion about its safety profile follows from its pharmacology rather than from a distinctive toxicity signal. A population pharmacokinetic modelling and target attainment analysis characterised dalbavancin exposures across dosing regimens and reported that the compound's prolonged terminal half-life sustains plasma concentrations for weeks after a single administration (PMID 31087630). An updated narrative review of therapeutic drug monitoring for methicillin-resistant S. aureus infections discussed dalbavancin among the antibiotics for which concentration measurement has been explored, and the authors reported that long-acting lipoglycopeptides raise monitoring questions that differ from those for short-acting intravenous agents (PMID 39209264).

This distinction is the reason adverse-event reporting for dalbavancin is framed differently in the literature than for daily-infusion antibiotics. Because exposure persists long after dosing, investigators in a pharmacokinetic and effectiveness study of treatment-experienced patients with skin, osteoarticular or vascular infections measured drug concentrations over extended follow-up while also recording clinical outcomes (PMID 36145630). Researchers writing the therapeutic drug monitoring review noted that this pharmacokinetic behaviour is central to how exposure is interpreted in practice and research (PMID 39209264).

Adverse Events in the Randomized Trial: What Studies Report

The strongest comparative safety information in the verified literature comes from a randomized clinical trial. The DOTS randomized clinical trial, published in JAMA in 2025, compared dalbavancin given as 1500 mg on day 1 and again on day 8 with standard-of-care intravenous antibiotic therapy in adults with complicated Staphylococcus aureus bacteremia, and the study reported adverse events alongside its clinical outcome measures (PMID 40802264). Because participants were randomly allocated, adverse events occurring in dalbavancin-treated participants in that trial could be compared with events in a concurrent comparator group receiving conventional therapy, which the trial report described for both arms (PMID 40802264).

Randomized comparison matters for side-effect interpretation. In bacteremia, patients frequently experience fever, laboratory abnormalities, line complications and new organ dysfunction as part of the infection itself, so a single-arm report cannot separate drug-related events from disease-related ones. Researchers conducting the DOTS trial addressed this by collecting outcome and adverse-event data in both the dalbavancin group and the standard-of-care group (PMID 40802264).

Adverse Events in Real-World Cohorts: What Studies Report

The remainder of the dalbavancin safety literature summarised here is observational. These reports described how the drug performed and was tolerated in specific clinical settings, usually retrospectively and usually without a randomized comparator.

Bone, joint and implant-associated infections

A two-centre Greek real-world retrospective study examined dalbavancin for bone and joint infections and reported clinical outcomes and tolerability in the treated cohort (PMID 41305347). A separate report in Arthroplasty Today described dalbavancin use in bone and joint infections and discussed the practical reasons clinicians turned to a long-acting agent in this population, including the length of therapy such infections require (PMID 39959367). A 2025 report examined dalbavancin as suppressive therapy for implant-associated osteoarticular infections, where dosing was repeated over extended periods, and the authors reported outcomes and safety observations under that prolonged-exposure approach (PMID 41301666).

Prolonged or repeated administration is the scenario in which cumulative exposure questions arise most clearly, and researchers described this explicitly in the suppressive-therapy cohort (PMID 41301666). The PEDDAL study reported real-world use of dalbavancin in diabetic foot osteomyelitis, a population characterised by peripheral vascular disease, renal impairment and multiple concurrent medications, and the authors described treatment outcomes in that setting (PMID 41095786).

Bloodstream and endocardial infections

A pilot study examined dalbavancin in catheter-related bloodstream infections and reported clinical results in that specific indication (PMID 37283643). A single-centre experience described dalbavancin use for infective endocarditis and reported the outcomes observed in the treated patients (PMID 33073724). Both were small and uncontrolled, and both dealt with infections in which severe complications are common irrespective of the antibiotic chosen, a limitation inherent to single-centre designs of the type reported in the endocarditis series (PMID 33073724).

Skin, vascular and outpatient settings

A clinical effectiveness and pharmacokinetic study in treatment-experienced patients with skin, osteoarticular or vascular infections combined outcome assessment with drug concentration measurement, and the researchers reported both effectiveness and pharmacokinetic findings in that mixed population (PMID 36145630). A separate report described dalbavancin use during the COVID-19 pandemic, when reducing hospital stay and infusion visits became a stated priority, and the authors discussed how a long-acting agent was applied under those conditions (PMID 36265122).

Tolerability and Treatment Discontinuation: What Studies Report

Across the observational literature summarised here, tolerability was generally recorded as a secondary observation rather than a primary endpoint. The Greek two-centre retrospective study reported tolerability alongside clinical effectiveness in bone and joint infection (PMID 41305347), and the implant-associated suppressive-therapy report described safety observations during repeated dosing (PMID 41301666). The catheter-related bloodstream infection pilot similarly reported clinical and safety observations within a small treated group (PMID 37283643).

Retrospective case-note review is the weakest method for capturing mild or transient adverse effects, because events not written into the record cannot be counted. This applies to the retrospective bone and joint dataset (PMID 41305347) and to the real-world diabetic foot osteomyelitis study (PMID 41095786). By contrast, prospective adverse-event collection in both arms was a feature of the randomized bacteremia trial (PMID 40802264).

Why the Long Half-Life Appears in Every Safety Discussion

A recurring theme in the pharmacology papers is that dalbavancin exposure cannot be rapidly reversed. The population pharmacokinetic and target attainment analysis quantified the extended concentration–time profile that follows administration (PMID 31087630), and the therapeutic drug monitoring review discussed how such extended exposure shapes the questions clinicians ask about monitoring (PMID 39209264). The study of treatment-experienced patients measured concentrations directly over follow-up, linking measured exposure to clinical course (PMID 36145630).

These papers are not adverse-event studies, but they explain why authors of the clinical cohorts paid attention to duration of exposure — particularly where dosing was repeated for suppressive purposes over months (PMID 41301666).

Use Beyond Labelled Indications: What Studies Report

Most of the cohorts summarised here involved infections outside the originally approved skin and soft-tissue indication. An expert consensus published in 2025 addressed how novel antimicrobials, including long-acting agents, have been used beyond official indications and described the reasoning, evidence gaps and cautions that the panel identified (PMID 41293551). That document is a consensus statement rather than trial data, and the authors framed their positions as expert opinion informed by available evidence (PMID 41293551). Readers comparing safety reports should note that off-label populations — prosthetic joints, endocarditis, diabetic foot osteomyelitis — differ substantially from the populations in which registration trials were performed, as reflected in the diabetic foot osteomyelitis dataset (PMID 41095786).

How the study designs compare

What the evidence does not settle

• Comparative rates. Only the randomized bacteremia trial reported adverse events against a concurrent comparator group (PMID 40802264); the cohorts described treated patients only, as in the endocarditis series (PMID 33073724).
• Small samples. The catheter-related bloodstream infection report was explicitly a pilot study (PMID 37283643), so rare events would not be expected to appear.
• Long-exposure data. Repeated dosing for suppression was described in a single 2025 cohort (PMID 41301666), and modelling papers characterised exposure rather than long-term outcomes (PMID 31087630).
• Off-label heterogeneity. An expert consensus noted evidence gaps for use beyond official indications (PMID 41293551).
• Monitoring practice. Whether concentration monitoring changes safety outcomes was discussed but not resolved in the therapeutic drug monitoring review (PMID 39209264).

Reading adverse-event reports critically

Three questions separate a meaningful safety signal from background noise in this literature. First, was there a comparator — a feature of the randomized bacteremia trial (PMID 40802264) and absent from single-centre series (PMID 33073724). Second, was adverse-event capture prospective or reconstructed from records, the latter being the case in retrospective real-world datasets (PMID 41305347). Third, was exposure single-dose or repeated, since repeated administration was the setting examined in the suppressive-therapy report (PMID 41301666) and pandemic-era outpatient use emphasised fewer administrations (PMID 36265122).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any antibiotic, infection or medication question. Dalbavancin is a prescription antibiotic, and decisions about its use, monitoring and adverse-event management belong to treating clinicians. Nothing here describes a regimen for any individual.

References

• Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial (JAMA, 2025)
• Dalbavancin During the COVID-19 Pandemic (Surgical Technology International, 2022)
• How to use novel antimicrobials beyond official indications: an expert consensus (JAC-Antimicrobial Resistance, 2025)
• Dalbavancin in catheter-related bloodstream infections: a pilot study (Le Infezioni in Medicina, 2023)
• Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study (Pathogens, 2025)
• Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections (Pharmaceutics, 2022)
• Dalbavancin as Suppressive Therapy for Implant-Associated Osteoarticular Infections (Antibiotics, 2025)
• Dalbavancin for infective endocarditis: a single centre experience (Journal of Chemotherapy, 2021)
• Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study (Journal of Clinical Medicine, 2025)
• Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis (Clinical Pharmacology in Drug Development, 2020)
• Dalbavancin Use in Bone and Joint Infections (Arthroplasty Today, 2024)
• Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians (Clinical Microbiology and Infection, 2025)